The Stanford Drug Discovery Symposium
The 2024 Stanford Drug Discovery Symposium (SDDS 2024) was held on April 29 and 30, 2024, in Berg Hall at Stanford’s Li Ka Shing Center, with a virtual option. The Stanford Cardiovascular Institute organized it and described it as a platform for interdisciplinary exchange at the forefront of drug research, serving researchers, pharmaceutical companies, and investors. Its program ran from opportunities and challenges in drug discovery, including the use of AI and machine learning in pharmaceutical research, to investing in drug ventures, funding, and translational research. Dr. Omar Costilla Reyes announced a week ahead that he would attend and invited friends and colleagues in Silicon Valley to meet and catch up on research and ventures in health and technology; on April 30 he posted from the symposium.
From discovery to treatment
Drug discovery is the process of finding a molecule that can safely change the course of a disease and then testing it in stages, from laboratory studies through clinical trials, before it can reach patients. The symposium’s range reflected how long that path is and how many kinds of expertise it needs: biology and chemistry, regulation, funding and, increasingly, computation. Dr. Costilla Reyes’s own work centers on healthcare AI, and he had become chief executive of Equ Healthcare that April.
Research conversation with Carolyn Bertozzi
During the Stanford visit he met Carolyn Bertozzi, whom he called one of his scientific heroes, and discussed opportunities in health impact and research in the context of the future of drug discovery and human healthcare. In the photograph, her speaker badge names her and Stanford University. Bertozzi received the 2022 Nobel Prize in Chemistry for developing click chemistry and bioorthogonal chemistry, methods that let researchers study biomolecules in living systems without disrupting their normal chemistry.